CLL | Tumor

CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.

Fixed-Duration Regimen More Cost-Effective Than Treat-Until-Progression Therapies in CLL

February 7th 2020

The novel drug pairing of Venclexta and Gazyva, used for a fixed 12 months, is cost-effective compared with regimens that must be taken until disease progresses, a study finds.

Choosing the Best Therapy for Patients with Chronic Lymphocytic Leukemia

January 17th 2020

With many targeted treatment options for patients with CLL to use upfront, the question arises as to which one is best for the individual.

Psychosocial Intervention for Caregivers May Improve Quality of Life

January 16th 2020

A brief, multimodal psychosocial intervention for caregivers of patients undergoing hematopoietic stem cell transplantation could improve their quality of life, caregiving burden and anxiety and depression symptoms.

Information at Your Fingertips

January 16th 2020

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with the associate director of the Information Resource Center at the Leukemia and Lymphoma Society on support groups and other recourses available for those affected by blood cancer.

Limiting Treatment Duration Improves Cost Effectiveness in CLL

January 5th 2020

Researchers are exploring ways to limit the duration of treatment in chronic lymphocytic leukemia in order to reduce costs.

Clinical Trial Participants May Fare Better Than Medicare Beneficiaries Treated with Zydelig

January 4th 2020

Those with follicular lymphoma and chronic lymphocytic leukemia who were treated with Zydelig in the clinical setting experienced less favorable outcomes, compared with those treated in a clinical trial.

A Look Back at the Top 10 CURE Stories of 2019

December 30th 2019

As 2019 comes to a close, take a read through CURE®’s top stories of the year.

CURE's Top 10 Podcasts of 2019

December 27th 2019

Take a look back at the top 10 podcasts of 2019 – and be sure to subscribe so you don’t miss an episode in 2020.

Don't Ignore Your Wake-Up Call

December 11th 2019

When one woman experienced symptoms of chronic lymphocytic leukemia, people blamed her nerves and told her to rest. Instead, she listened to her body.

Ibrutinib and Rituximab Improve Progression-Free Survival for Patients with CLL

December 10th 2019

Results presented at ASH 2019 suggest the combination therapy is superior to chemoimmunotherapy.

What Patients With CLL/SLL Should Know About the FDA's Approval of Calquence

November 28th 2019

The Food and Drug Administration’s approval of Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option, according to Dr. John C. Byrd.

FDA Approves Calquence for Leukemia and Lymphoma Subsets

November 21st 2019

In partnership with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the Food and Drug Administration (FDA) has granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

A Fortunate Turn of Events in Chronic Lymphocytic Leukemia

September 17th 2019

In what was once an incurable cancer — chronic lymphocytic leukemia — scientists are seeing remissions that could last for decades.

CURE's Top 5 Stories: July 2019

August 1st 2019

Here are the top 5 CURE stories for July 2019.

FDA Approves Biosimilar Ruxience: Here's What You Need to Know

July 24th 2019

With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.

FDA Approves Rituxan Biosimilar to Treat Blood Cancers

July 23rd 2019

The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.

Be Your Own Advocate

June 18th 2019

Patients with chronic lymphocytic leukemia should learn about the latest advancements, says one expert.

Venclexta Plus Gazyva Reduces Disease Progression by 65% in Patients with CLL

June 6th 2019

The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic leukemia.

Combination Therapies Offer Newer Options for CLL Treatment

May 31st 2019

Patients with chronic lymphocytic leukemia have newer options that include targeted therapy combinations and CAR-T cell therapy.

FDA Approves Venclexta-Gazyva Combo as Frontline Treatment for CLL/SLL

May 15th 2019

The Food and Drug Administration has approved the combination use of Venclexta plus Gazyva for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

CLL Patient Advocate Helped Many

May 13th 2019

Christopher Harington Dwyer, founder of CLL Canada and online chat contributor, leaves a legacy of support and knowledge.

Calquence Significantly Improves Survival in Patients with Chronic Lymphocytic Leukemia

May 7th 2019

The Bruton tyrosine kinase inhibitor showed a statistically-significant and clinically-meaningful improvement in progression-free survival in patients with previously-treated CLL.

Cancer Survivorship and the Mysterious 'New Normal'

May 3rd 2019

Most people have heard the term "new normal" for individuals living, surviving and struggling with cancer. What actually does that mean?

Risk for Disease Progression Changes Over Time in CLL, Depending on Somatic Mutations

April 30th 2019

Risk for disease progression among patients with chronic lymphocytic leukemia over time differed between those with mutated or unmutated disease, showing that gene somatic hypermutation plays a role throughout the disease course.

Novel Agents Show Promise in Chronic Lymphocytic Leukemia

April 4th 2019

An expert discusses new treatment options for patients diagnosed with CLL.

Changing Treatment Options Offer Next Advances in Chronic Lymphocytic Leukemia

April 3rd 2019

Patients with relapsed or refractory chronic lymphocytic leukemia may have more options now than ever before, according to William G. Wierda, M.D., Ph.D.

Front-line Combinations with New Agents Evolve Chronic Lymphocytic Leukemia Landscape

April 2nd 2019

While novel agents continue to evolve in the treatment landscape for chronic lymphocytic leukemia, many may start to be combined in the front-line setting as well, according to Matthew S. Davids, M.D., MMSc.

Shorter Treatment with Venclexta May Save Costs for Some With CLL

March 8th 2019

Time-limited treatment could be the new wave of research in the treatment of chronic lymphocytic leukemia (CLL), according to Nicole Lamanna, M.D.

CURE's Top 5 Stories: February 2019

March 1st 2019

Here are the top 5 CURE stories for February 2019.

Diagnosis

February 20th 2019

A CLL diagnosis comes with new challenges, from understanding signs and symptoms and what the different stages mean.

NEXT PAGE
PREVIOUS PAGE